News
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral ...
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
17m
InvestorsHub on MSNMustang Bio Shares Surge After FDA Grants Orphan Drug StatusMustang Bio Inc (NASDAQ:MBIO) stock soared over 78% following the U.S. Food and Drug Administration’s orphan drug designation for its MB-101 therapy targeting recurrent diffuse and anaplastic ...
The steady erosion of experienced staff is slowly compromising FDA work and low morale is pushing more workers to the exit ...
In an ongoing Phase 1 trial published in Nature Medicine, MB-101 was well-tolerated and 50% of patients achieved stable ...
The FDA granted orphan drug designation to Sineugene Therapeutics' SNUG01, a first-in-class experimental gene therapy for ...
1don MSN
NIH budget cuts are threatening key medical research programs, shrinking training grants, and leaving young researchers ...
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...
These recent food recalls involve cream cheese, eggs, shrimp, and ice cream due to serious health risks including salmonella ...
Americans are increasingly demanding that chemicals and toxic food dyes be removed from items they consume, clean with, wear, ...
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary swelling disorder, sending its shares up 33.3% in premarket trading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results